Healthcare technology firm Cue Health has selected Cardinal Health to distribute its molecular Covid-19 tests.
The company’s professional use and over-the-counter Covid-19 molecular tests will now be available through the Cardinal Health distribution network for pharmacies, hospitals and non-clinical consumer markets.
The tests will be available for health professionals and other qualified point-of-care test users and include the Cue COVID-19 Test for CLIA Certified Healthcare Providers and Laboratories (Professional), the Cue Health Monitoring System, and Cue COVID-19 Test Positive Control Swabs and Test Negative Control Swabs.
Cue Health stated that the collaboration with Cardinal Health will help speed up the reach of the company’s nucleic acid amplification test (NAAT) into non-traditional and traditional healthcare settings.
Cue Health co-founder and CEO Ayub Khattak said: “Customers across the country trust Cardinal Health to deliver high-quality laboratory products, and Cue shares a goal with them of placing diagnostic information at the centre of care.
“We look forward to making Cue’s highly accurate, fast and easy-to-use testing and access to real-time health information more widely available through our collaboration with Cardinal Health.”
The company noted that the Cue COVID-19 Test for Home and Over The Counter (OTC) Use (OTC/Home) is also available through the Cardinal Health distribution network.
It is claimed to be the first molecular diagnostic test of any kind that is available for use at home or in other non-clinical settings without a prescription.
Through the Cue Health App, the rechargeable Cue Health Monitoring System (Reader) securely sends results to the mobile smart device of the user in 20 minutes.
Furthermore, the company provides in-app supervised testing through its Cue+ membership programme and 24/7 on-demand virtual care from board-certified physicians.